REATA PHARMACEUTICALS INC Contracts & Agreements

Amended and Restated Termination of Expansion Agreements dated October 15, 2019, by and between TC Legacy Land Venture LLC, and Reata Pharmaceuticals, Inc (Filed With SEC on August 8, 2023)

Employment Agreement by and between the Company and Rajiv Patni, dated as of June 12, 2023 (Filed With SEC on August 8, 2023)

Indemnification Agreement by and between the Company and Rajiv Patni, dated as of June 12 2023 (Filed With SEC on August 8, 2023)

Amendment No. 2 to Lease Agreement dated October 15, 2019, as amended by the First Amendment to Lease Agreement, dated May 27, 2020 (Filed With SEC on August 8, 2023)

Agreement and Plan of Merger, dated as of July 28, 2023, by and among Reata Pharmaceuticals, Inc., Biogen Inc. and River Acquisition, Inc (Filed With SEC on July 31, 2023)

Seventh Supplement to Exclusive License and Supply Agreement, dated as of February 28, 2022 between Reata Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on August 8, 2022)

Indemnification Agreement by and between the Company and Steven W. Ryder, dated as of July 11, 2022. (incorporated by reference to Exhibit 10.2 to the Companys Form 8-K (File No.... (Filed With SEC on August 8, 2022)

Indemnification Agreement by and between the Company and Steven W. Ryder, dated as of July 11, 2022 (Filed With SEC on July 12, 2022)

Seventh Supplement to Exclusive License and Supply Agreement, dated as of February 28, 2022 between Reata Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on May 10, 2022)

Amendment No. 1 to Exclusive License Agreement, dated as of April 5, 2022, by and between the KU Center for Technology Commercialization, Inc. and the Registrant, dated as of, as... (Filed With SEC on May 10, 2022)

Exclusive License Agreement between the KU Center for Technology Commercialization, Inc. and the Registrant, dated as of September 26, 2014 (Filed With SEC on February 28, 2022)

Exclusive License and Supply Agreement between the Registrant and Kyowa Hakko Kirin Co. Ltd., dated as of December 24, 2009 (Filed With SEC on February 28, 2022)

Indemnification Agreement by and between the Company and Samina Khan, dated as of February 24, 2020 (Filed With SEC on February 28, 2022)

Indemnification Agreement by and between the Company and Andrea Loewen, dated as of February 24, 2020 (Filed With SEC on February 28, 2022)

Employment Agreement by and between the Company and Samina Khan, dated as of July 7, 2020 (Filed With SEC on February 28, 2022)

Employment Agreement by and between the Company and Andrea Loewen, dated as of February 24, 2020 (Filed With SEC on February 28, 2022)

Exclusive Patent License Agreement among the Board of Regents of The University of Texas System, The University of Texas M.D. Anderson Cancer Center, and the Trustees of Dartmouth... (Filed With SEC on February 28, 2022)

Exclusive License Agreement between the Trustees of Dartmouth College and the Registrant, dated as of December 16, 2009, as amended (Filed With SEC on February 28, 2022)

Amendment No. 2 to the Exclusive License Agreement between the Trustees of Dartmouth College and the Registrant, dated as of August 17, 2021 as amended (Filed With SEC on November 8, 2021)

Amendment No. 2 to the Exclusive Patent License Agreement among the Board of Regents of The University of Texas System, The University of Texas M.D. Anderson Cancer Center, and... (Filed With SEC on November 8, 2021)

Notice of Grant of Restricted Stock Units for employees, dated as of December 2, 2020 (Filed With SEC on May 6, 2021)

Indemnification Agreement by and between the Company and Shamim Ruff, dated as of April 15, 2021 (Filed With SEC on April 15, 2021)

Indemnification Agreement by and between the Company and Christy J. Oliger, dated as of April 15, 2021 (Filed With SEC on April 15, 2021)

Fifth Amended and Restated Non-Employee Director Compensation Policy, dated as of December 2, 2020 (Filed With SEC on March 1, 2021)

Notice of Grant of Restricted Stock Units for director/consultants, dated as of December 2, 2020 (Filed With SEC on March 1, 2021)

Underwriting Agreement, dated December 1, 2020, by and among Reata Pharmaceuticals, Inc. and the Representatives (Filed With SEC on December 3, 2020)

Fourth Amended and Restated Non-Employee Director Compensation Policy, dated as of June 10, 2020 (Filed With SEC on August 10, 2020)

Development and Commercialization Funding Agreement between the Company and BXLS V River L.P, dated as of June 10, 2020 (Filed With SEC on August 10, 2020)

Common Stock Purchase Agreement between the Company and BXLS V River L.P, dated as of June 10, 2020 (Filed With SEC on August 10, 2020)

First Amendment to Lease Agreement, dated as of May 27, 2020 (Filed With SEC on August 10, 2020)

Indemnification Agreement by and between the Company and Martin W. Edwards, dated as of August 3, 2020 (Filed With SEC on July 31, 2020)

Third Amended and Restated Non-Employee Director and Compensation Policy dated as of December 11, 2019 (Filed With SEC on February 19, 2020)

Denbury Lease Expansion Agreement, dated December 12, 2019 (Filed With SEC on February 19, 2020)

Gateway Lease Expansion Agreement, dated December 12, 2019 (Filed With SEC on February 19, 2020)

Notice of Grant of Restricted Stock Units for employees (Filed With SEC on February 19, 2020)

Description of Registrants Securities (Filed With SEC on February 19, 2020)

Underwriting Agreement, dated November 13, 2019, by and among Reata Pharmaceuticals, Inc. and the Representatives (Filed With SEC on November 14, 2019)

Employment Agreement by and between the Company and Manmeet S. Soni dated August 28, 2019 (Filed With SEC on November 12, 2019)

Indemnification Agreement by and between the Company and Manmeet S. Soni dated August 28, 2019 (Filed With SEC on November 12, 2019)

Notice of Grant of Restricted Stock Units for employees (Filed With SEC on November 12, 2019)

Restricted Stock Unit Agreement (Filed With SEC on November 12, 2019)

Amended and Restated License Agreement, dated as of October 9, 2019 (Filed With SEC on October 10, 2019)

First Amendment to Amended and Restated Loan and Security Agreement, dated as of October 9, 2019 (Filed With SEC on October 10, 2019)

Sixth Supplement to Exclusive License and Supply Agreement, dated August 22, 2019, between Reata Pharmaceuticals, Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on August 22, 2019)

Fifth Supplement to Exclusive License and Supply Agreement, dated August 22, 2019, between Reata Pharmaceuticals, Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on August 22, 2019)

Reata Pharmaceuticals, Inc. Second Amended and Restated Long Term Incentive Plan (Filed With SEC on May 9, 2019)

Stock Option Agreement (Filed With SEC on May 9, 2019)

Notice of stock option grant forms for employees and director/consultant (Filed With SEC on May 9, 2019)

Notice of Stock Option Grant forms for employees and director/consultants (Filed With SEC on February 28, 2019)

Second Amended and Restated Non-Employee Director Compensation Policy dated as of December 11, 2018 (Filed With SEC on February 28, 2019)

Underwriting Agreement, dated July 24, 2018, by and among Reata Pharmaceuticals, Inc. and the Underwriters named therein (Filed With SEC on July 26, 2018)

Amended and Restated Loan and Security Agreement, dated as of June 14, 2018, by and among Reata Pharmaceuticals, Inc., as borrower, Oxford Finance LLC, as the collateral agent and... (Filed With SEC on June 14, 2018)

Amended and Restated Non-Employee Director Compensation Policy dated as of December 6, 2017 (Filed With SEC on March 2, 2018)

Fourth Supplement to Exclusive License and Supply Agreement, dated as of December 6, 2017, between Reata Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on December 7, 2017)

Third Supplement to Exclusive License and Supply Agreement, dated as of December 6, 2017, between Reata Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on December 7, 2017)

Lease Amendment No. 11, effective as of November 9, 2017, between Reata Pharmaceuticals, Inc. and SDCO Gateway Commerce I & II, Inc (Filed With SEC on November 13, 2017)

At-the-Market Equity Offering Sales Agreement, dated November 9, 2017, between Reata Pharmaceuticals, Inc., and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on November 13, 2017)

First Amendment to Loan and Security Agreement, dated as of November 3, 2017, by and among Reata Pharmaceuticals, Inc., as borrower, Oxford Finance LLC, as the collateral agent... (Filed With SEC on November 7, 2017)

3,250,000 Shares Class A Common Stock ($0.001 par value per share) Underwriting Agreement (Filed With SEC on July 28, 2017)

LOAN AND SECURITY AGREEMENT (Filed With SEC on April 3, 2017)

REATA PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on March 3, 2017)

REATA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on March 2, 2017)

REATA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on November 14, 2016)

EMPLOYMENT AGREEMENT by and between Reata Pharmaceuticals, Inc. and Jason D. Wilson (Filed With SEC on November 14, 2016)

EMPLOYMENT AGREEMENT by and between Reata Pharmaceuticals, Inc. and Michael D. Wortley (Filed With SEC on November 14, 2016)

EMPLOYMENT AGREEMENT by and between Reata Pharmaceuticals, Inc. and Dawn Carter Bir (Filed With SEC on November 14, 2016)

Reata Pharmaceuticals, Inc. 5,500,000 Shares Class ACommon Stock ($0.001 par value per share) Underwriting Agreement (Filed With SEC on May 26, 2016)

REATA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on May 20, 2016)

REATA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2007 LONG TERM INCENTIVE PLAN (Filed With SEC on March 22, 2016)

SUPPLEMENT TO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT Regarding Phase 3 Clinical Study (CTD-PAH) in Japan (Filed With SEC on March 22, 2016)

Reata Pharmaceuticals, Inc. [] Shares Class ACommon Stock ($0.001 par value per share) Underwriting Agreement (Filed With SEC on February 8, 2016)

LICENSE AGREEMENT between REATAPHARMACEUTICALS, INC. and ABBOTT PHARMACEUTICALS PR LTD. Dated as of September 21, 2010 TABLE OF CONTENTS (Filed With SEC on February 8, 2016)

EMPLOYMENT AGREEMENT by and between ReataPharmaceuticals, Inc. and J. Warren Huff (Filed With SEC on January 4, 2016)

REATAPHARMACEUTICALS, INC. EIGHTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT (Filed With SEC on January 4, 2016)

REATAPHARMACEUTICALS, INC. SEVENTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (Filed With SEC on January 4, 2016)

REATA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on January 4, 2016)

REATA PHARMACEUTICALS, INC. AMENDED AND RESTATED 2007 LONG TERM INCENTIVE PLAN (Filed With SEC on January 4, 2016)

EMPLOYMENT AGREEMENT byand between Reata Pharmaceuticals, Inc. and Keith W. Ward,Ph.D. (Filed With SEC on January 4, 2016)

LICENSE AGREEMENT between REATAPHARMACEUTICALS, INC. and ABBOTT PHARMACEUTICALS PR LTD. Dated as of September 21, 2010 TABLE OF CONTENTS (Filed With SEC on January 4, 2016)

EXCLUSIVE LICENSE and SUPPLY AGREEMENT by and between REATAPHARMACEUTICALS, INC. and KYOWA HAKKO KIRIN CO. LTD. (Filed With SEC on January 4, 2016)

EXCLUSIVE LICENSE AGREEMENT between ReataPharmaceuticals, Inc. and KU Center for Technology Commercialization, Inc. (Filed With SEC on January 4, 2016)

REATA PHARMACEUTICALS, INC. - DARTMOUTH EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on January 4, 2016)

EXCLUSIVE PATENT LICENSE AGREEMENT AMONG THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER DARTMOUTH COLLEGE AND REATA DISCOVERY, INC. TABLE OF CONTENTS (Filed With SEC on January 4, 2016)

LEASE SDCO GATEWAYCOMMERCE I & II, INC., Landlord, and REATAPHARMACEUTICALS, INC., Tenant TABLE OF CONTENTS (Filed With SEC on January 4, 2016)

EMPLOYMENT AGREEMENT byand between Reata Pharmaceuticals, Inc. and Colin J. Meyer, MD (Filed With SEC on January 4, 2016)

Category

Industry

Companies

Contracts

REATA PHARMACEUTICALS INC Contracts & Agreements